About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Perception of Symptom Variability in COPD | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT01753427

Perception of Symptom Variability in COPD

The objective of the study is to assess patient's perception with stable state COPD on symptom variability and to describe how symptom variability impacts daily quality of life in Chinese COPD patient...

Lead sponsor: AstraZeneca•6 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Provision of subject informed consent
•Out-patient
•Clinical diagnosis of COPD at least 6 months
•Lung function based on data available within 3 months in medical records confirming FEV1\<80% normal predicted (post-bronchodilator) and FEV1/FVC\<0.7 (post-bronchodilator)

Exclusion Criteria

•Participation in any interventional study involving investigational drugs; Patient inability to understand the study procedures or inability/reluctance to answer questionnaire
•Ongoing exacerbation of COPD or exacerbation within the previous 3 months. An exacerbation is defined as a worsening of COPD symptoms leading to a treatment with antibiotics and/or a short course of system steroids and/or hospitalisation or emergency
•History of asthma and/or allergic rhinitis, Lung cancer or any other significant respiratory disease such as bronchiectasis, lung fibrosis, interstitial lung disease, tuberculosis, sarcoidosis

Related studies

CLEAR Model for Predicting Ventilatory Liberation in Severe COPD

NCT07579052 · Chronic Obstructive Pulmonary Disease

Pulmonary Rehabilitation for Rural Patients With COPD

NCT06847061 · Chronic Obstructive Pulmonary Disease (COPD

RECRUITINGPhase 2

Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD

NCT05061368 · Chronic Obstructive Pulmonary Disease

RECRUITINGPhase 1/2

Feasibility of Semaglutide in Advanced Lung Disease

NCT05746039 · Obesity, Interstitial Lung Disease, and more

RECRUITINGPhase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209 · Chronic Obstructive Pulmonary Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 15, 2016Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment1,058

Start dateDec 2012

Last updatedJun 15, 2016

Condition

Chronic Obstructive Pulmonary Disease

Locations shown

Research Site

Beijing, Beijing Municipality

Research Site

Guangzhou, Guangdong

Research Site

Wuhan, Hubei

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 15, 2016Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions